Iterative Scopes, provider of precision medicine technologies for gastroenterology, has entered into a data sharing agreement with Pfizer to accelerate the development of potential new treatments for patients suffering from IBD by standardising endoscopic interpretation.
Currently, disease severity scoring systems, such as the Mayo Endoscopic Score (MES), are used to meet inclusion criteria in IBD clinical trials and to measure primary and secondary endpoints. These metrics are highly subjective and dependent on physician experience and intuition. They also present patient recruitment and workflow challenges.
According to Iterative Scopes, its computational algorithms resolve these challenges when integrated with existing colonoscopy imagery to determine clinical trial eligibility. The company’s computational software automates interpretation of colonoscopy videos, enabling clinical trial investigators to arrive at standardised MES scores for individual patients.
“We are excited to harness machine learning and computer vision to ultimately aid physicians and help them improve clinical outcomes for IBD patients earlier and with greater success,” said Jean-Pierre Schott, Senior VIce President of Engineering at Iterative Scopes. “This agreement will leverage certain Pfizer patient research along with the Iterative Scopes technological advancements to assess colon health faster and with greater granularity, and possibly improve the quality of life for thousands of patients.”